Dublin, July 05, 2024 (GLOBE NEWSWIRE) — The “Non-Cystic Fibrosis Bronchiectasis Market – Global Industry Size, Share, Trends, Opportunity and Forecast, 2019-2029F” report has been added to ResearchAndMarkets.com’s offering.
Global Non-Cystic Fibrosis Bronchiectasis Marketwas valued at USD 3.52 Billion in 2023 and is anticipated to project steady growth in the forecast period with a CAGR of 5.25% through 2029
Non-cystic fibrosis bronchiectasis (NCFB) presents a chronic respiratory ailment characterized by abnormal widening and scarring of airways, leading to mucus buildup and recurrent respiratory infections. The global NCFB market is experiencing growth due to heightened awareness, improved diagnostics, and innovative treatments. Factors such as increased disease prevalence, better healthcare professional awareness, and diagnostic advancements are propelling this growth. Bronchiectasis affects all age groups and is a growing public health concern globally.
Advanced diagnostic tools like high-resolution computed tomography (HRCT) scans have enhanced diagnosis accuracy, allowing for timely treatment. Rising awareness among healthcare providers and patients, driven by educational initiatives and advocacy, results in earlier intervention. In addition, the development of new therapies such as inhaled antibiotics and mucolytics offers more effective solutions. With the aging global population, NCFB incidence is projected to escalate, further stimulating market expansion.
Technological Advancements
The healthcare sector is continually advancing, driven by technological innovations and progressive research. A notable area witnessing this evolution is the treatment and management of non-cystic fibrosis bronchiectasis (NCFB). NCFB, a chronic and progressive lung condition affecting bronchial tubes, manifests symptoms such as chronic cough, excessive mucus production, and recurrent infections. The ongoing progress in medical technology significantly influences the global NCFB market.
Advancements in telemedicine and remote monitoring technologies are revolutionizing patient care. These innovations facilitate easier access to healthcare professionals and enable patients to manage their condition remotely. Through digital platforms, patients can connect with healthcare providers, share health data, and receive real-time guidance, reducing the necessity for frequent in-person visits. As well, technological progress in drug development has resulted in more effective NCFB treatments. Emerging medications, including inhaled antibiotics and mucolytics, demonstrate promise in symptom reduction and exacerbation prevention, potentially reshaping NCFB management with more efficient and convenient options.
Genomic and biomarker research advancements enable personalized treatment approaches for NCFB patients. By analyzing individual genetic profiles and specific biomarkers, healthcare providers can customize treatment strategies to meet each patient’s distinct needs. This precision medicine approach enhances therapy effectiveness while minimizing adverse effects. Mobile applications, online support communities, and patient education platforms facilitate NCFB information access, experience sharing, and treatment plan involvement. Technological tools empower patients to proactively manage their condition, leading to improved outcomes and enhanced quality of life.
Segmental Insights
Treatment Insights
Based on the category of Treatment, surgery emerged as the dominant player in the global market for Non-Cystic Fibrosis Bronchiectasis in 2023.In severe cases of Non-Cystic Fibrosis Bronchiectasis (NCFB), when a specific lung section is severely damaged and unresponsive to other therapies, surgical resection may be necessary. Surgeons remove the damaged lung portion, enabling the remaining healthy tissue to operate more efficiently. A less invasive surgical approach involves the insertion of endobronchial valves.
These valves, operating in one direction, block airways leading to damaged lung tissue, redirecting airflow to healthier areas. This procedure can enhance lung function and improve patients’ quality of life. Bronchial thermoplasty is an innovative procedure delivering controlled thermal energy to airway walls, reducing excessive smooth muscle in the bronchi. This treatment can alleviate bronchospasm and enhance airway function in NCFB patients. Surgical interventions also address NCFB complications like bronchial strictures or obstructions. Procedures aimed at clearing or widening airways can significantly enhance breathing and quality of life.
End use Insights
TheHospitals Clinics segment is projected to experience rapid growth during the forecast period. Early diagnosis and intervention play a pivotal role in effectively managing Non-Cystic Fibrosis Bronchiectasis (NCFB). Hospitals and clinics serve as primary points of contact for patients exhibiting respiratory symptoms, making them integral in the timely identification of NCFB cases.
Physicians and pulmonologists in these healthcare facilities possess the requisite tools and expertise to diagnose NCFB through a combination of clinical assessment, imaging studies (such as high-resolution computed tomography or HRCT), and pulmonary function tests. Besides, the establishment of specialized respiratory clinics within hospitals has enhanced diagnostic accuracy and timeliness. Early identification and treatment of NCFB not only enhance patients’ quality of life but also mitigate healthcare costs associated with managing advanced disease stages.
Hospitals and clinics lead the forefront in NCFB management, offering a diverse array of treatment modalities. These facilities provide access to healthcare professionals specializing in respiratory medicine, ensuring personalized care for patients. Treatment approaches for NCFB encompass bronchodilators, mucus-thinning medications, antibiotics, and, when necessary, surgical interventions for lung tissue removal. In addition, hospitals often host pulmonary rehabilitation programs tailored to improve lung function, enhance exercise capacity, and educate patients on symptom management. The provision of requisite infrastructure and personnel support for these programs underscores hospitals’ and clinics’ significant contributions to the overall well-being of NCFB patients.
Regional Insights
North America emerged as the dominant player in the global Non-Cystic Fibrosis Bronchiectasis market in 2023, holding the largest market share in terms of value. The region hosts numerous clinical trials, funded research, and academic institutions dedicated to NCFB. These studies aim to understand the pathophysiology of the disease, develop novel therapies, and improve diagnosis and management. North America has seen a surge in pharmaceutical companies investing in the development of new therapies for NCFB.
This has led to the introduction of innovative treatments that target the underlying causes of the disease and improve the quality of life for patients. Patient advocacy groups in North America have played a pivotal role in raising awareness about NCFB and advocating for better care and support for those affected by the condition. They work to ensure that patients have access to the latest treatments and information.
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 185 |
| Forecast Period | 2023 – 2029 |
| Estimated Market Value (USD) in 2023 | $3.52 Billion |
| Forecasted Market Value (USD) by 2029 | $4.8 Billion |
| Compound Annual Growth Rate | 5.2% |
| Regions Covered | Global |
Competitive Landscape
- Novartis AG
- Pfizer Inc.
- Bayer AG
- Viatris Inc.
- Teva Pharmaceutical Industries Ltd.
- GSK plc
- F. Hoffmann-La Roche Ltd.
- Sun Pharmaceutical Industries Ltd.
- Aurobindo Pharma Ltd.
- Dr. Reddy’s Laboratories Ltd
Report Scope:
Non-Cystic Fibrosis Bronchiectasis Market, By Treatment:
- Surgery
- Physiotherapy
- Vaccination
- Airway Pharmacotherapy
- Antibiotics
- Others
Non-Cystic Fibrosis Bronchiectasis Market, By Diagnosis:
- CT scan
- Bronchoscopy
- Chest X-ray
- Lung function
- Sputum culture test
- Blood Tests
- Others
Non-Cystic Fibrosis Bronchiectasis Market, By End use:
- Hospitals Clinics
- Ambulatory Care Centers
- Others
Non-Cystic Fibrosis Bronchiectasis Market, By Region:
- North America
- United States
- Canada
- Mexico
- Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
- Asia-Pacific
- China
- India
- Japan
- Australia
- South Korea
- South America
- Brazil
- Argentina
- Colombia
- Middle East Africa
- South Africa
- Saudi Arabia
- UAE
For more information about this report visit https://www.researchandmarkets.com/r/f66h3w
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
- Global Non-Cystic Fibrosis Bronchiectasis Market
